Skip to content

Regenxbio

US · RGNX #3748 by market cap Listed 2015
7.16 -0.02 -0.28%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:41

Price chart

Pre-market 7.10 -1.11%
After-hours 7.12 -0.56%
15.656.087.162026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on RGNX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -34.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 15.4% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days E → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall C+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth B+

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 14.8% Better than 75%
Net income CAGR (3Y) 8.6% Better than 56%
Free cash flow CAGR (3Y) 13.8% Better than 58%
Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 88.1% Better than 95%
Operating margin -94.6% Better than 7%
Net margin -113.8% Better than 7%
Return on equity -107.0% Better than 5%
Return on invested capital -57.5% Better than 5%
Momentum C-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -33.2% Better than 15%
6-month return 12.8% Better than 75%
12-month return (ex latest month) -39.2% Better than 5%
Distance below 52-week high 55.8% Better than 14%
Financial Health C+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 2.4x Better than 64%
Debt to assets 16.2% Better than 61%
Interest coverage -3.3x Better than 18%
Free cash flow / net income 105.4% Better than 42%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 81.8% Better than 62%
Upside to average target 192.0% Better than 94%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -6.28%
1M -3.24%
3M -35.26%
6M +19.93%
YTD -50.28%
1Y -34.13%
3Y -64.25%
5Y -78.63%

Key statistics

Price & volume

Prev close
7.18
Open
7.00
Day range
6.86 - 7.30
Avg price
7.12
Volume
1.06M
Turnover
7.57M
Amplitude
6.13%
52-week range
5.46 - 16.19

Valuation

P/E
-1.90
P/E (TTM)
-2.24
P/B
3.20
EPS
-3.76
Net profit
-248.62M
Net assets
148.05M

Share structure

Market cap
473.44M
Float cap
405.49M
Shares out
66.12M
Float shares
56.63M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2015-09-17
52-week range 16% of range
5.46 16.19

55.8% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-2.66M net over the window

Short interest

Shares short
10.18M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Regenxbio (RGNX)?

Regenxbio last traded at 7.16. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Regenxbio's market cap?

About 473.44M.

What is the P/E ratio of Regenxbio?

The trailing twelve-month P/E is -2.24, below its own 5-year average of 0.16 — in the middle of its historical range (49.88% percentile). See the Valuation tab for the full history.

Does Regenxbio pay a dividend?

Regenxbio does not currently pay a regular dividend.

Is Regenxbio a buy according to analysts?

The consensus of 11 analysts is a Buy rating, with an average 12-month price target of 20.91, which implies 192.0% upside from the current price. This is not investment advice.

What is Regenxbio's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Regenxbio a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 19:41:20 · For reference only, not investment advice and not tailored to your situation.

Regenxbio discussion 0 comments

Add a comment